Is Amgen Inc. (AMGN) a Cheap NASDAQ Stock to Buy According to Hedge Funds?
From Yahoo Finance: 2025-04-22 09:49:00
- Dan Ives of Wedbush Securities predicts major volatility in the tech sector due to ongoing uncertainty, with large tech purchases being downsized or paused as companies approach earnings season. Tariffs on China have forced companies to reconsider importing costs, resulting in a notable pause in tech spending. Street estimates are expected to see earnings cuts of about 10% across internet and big tech companies, reflecting the broader pullback in spending and ongoing volatility.
- Amgen Inc. (NASDAQ:AMGN) is a cheap NASDAQ stock to buy according to hedge funds, with a forward P/E ratio of 13.33 and 72 hedge fund holders. The company focuses on developing and delivering human therapeutics, with medications like Repatha and EVENITY driving significant sales growth in 2024.
- Amgen Inc. (NASDAQ:AMGN) ranks 11th on the list of cheap NASDAQ stocks to buy according to hedge funds. Despite the growth potential of AMGN, there is a promising AI stock with significant upside potential trading at less than 5 times its earnings. Investors looking for high returns within a shorter time frame may want to explore this opportunity.
Read more at Yahoo Finance: Is Amgen Inc. (AMGN) a Cheap NASDAQ Stock to Buy According to Hedge Funds?